Could zapping the brain ease stubborn eye pain?

NCT ID NCT05931250

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This pilot study tests whether two types of gentle brain stimulation—transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS)—can reduce chronic neuropathic eye pain and related symptoms like brain fatigue, migraine, and light sensitivity. Twenty patients with persistent eye pain will receive fifteen 30-minute sessions over five days. The study uses questionnaires and pupil measurements to track changes in pain and other symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial current stimulation (tDCS and tACS)
What this could lead to
If effective, this approach could offer a non-drug option for managing chronic neuropathic eye pain and associated symptoms like fatigue and light sensitivity.
What could go wrong
This is a small pilot study with only 20 participants, so results may not apply broadly. The treatment is experimental and may not provide lasting pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * persistent eye pain for at least 6 months * average eye pain intensity of 4 or more on a 0-10 numerical rating scale * naive to transcranial stimulation * eye pain having neuropathic-like characteristics Exclusion Criteria: * contraindication to transcranial stimulation (i.e., pacemaker, cardioverter defibrillator, neuro-stimulation (brain or spinal cord), bone growth stimulations, indwelling blood pressure monitors, epilepsy, pregnancy) * presence of ocular diseases that are the likely cause of pain (i.e., corneal and conjunctival scarring, corneal edema, uveitis, iris transillumination defects, etc.) * current participation in another study with an investigational drug or device within one month prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eye Clinic, University Hospital in Linköping

    Linköping, Other / Non-US, 58183, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.